Macrophage-mediated antibody dependent effector function in aggressive B-cell lymphoma treatment is enhanced by Ibrutinib via inhibition of JAK2
V. Barbarino, S. Henschke, S. Blakemore, E. Izquierdo, M. Michalik, R. Brinker, N. Nickel, I. Moellenkotte, D. Vorholt, O. Fedorchenko, N. Mikhael, T. Seeger-Nukpezah, M. Hallek, C. P. Pallasch
The paper shows ibrutinib enhances macrophage-mediated antibody-dependent cellular phagocytosis in B-cell lymphoma by inhibiting JAK2, improving treatment outcomes.
bioRxiv · Jun 10, 2020Cancer Biology